Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay

Diseases of the Colon and Rectum

Volumn 39, Issue 4, 1996, Pages 416-422

  Yamaue, Hiroki ^a   Tanimura, Hiroshi ^a   Nakamori, Mikihito ^a   Noguchi, Kohei ^a   Iwahashi, Makoto ^a   Tani, Masaji ^a   Hotta, Tsukasa ^a   Murakami, Koichi ^a   Ishimoto, Kiwao ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemosensitivity test; Chemotherapy; Colorectal cancer; MTT assay

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COLORIMETRY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAPLEURAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN;

EID: 0029870844     PISSN: 00123706     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02054057     Document Type: Article

References (30)

1. Higgins GA, Humphrey E, Juler GL, LeVeen HH, McCaughan J, Keehn RJ. Adjuvant chemotherapy in the surgical treatment of large bowel cancer. Cancer 1976; 38:1461-67.
2. Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer: results of a prospectively randomized trial. N Engl J Med 1984;310:737-43.
3. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465-72.
4. Shah A, MacDonald W, Goldie J, Gudauskas G, Brisebois B. 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. Cancer Treat Rep 1985;69:739-42.
5. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21-9.
6. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988;80:30-6.
7. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709-15.
8. Agrez MV, Lieber MM. In vitro chemotherapy sensitivity testing of primary human colorectal carcinomas. J Surg Oncol 1983;22:269-72.
9. ®, Mitornycin C, Aclacinomycin A, cisplatin, 5-fluorouracil. Dis Colon Rectum 1988;31:62-7.
10. Ueo H, Maehara Y, Saito A, Sakaguchi Y, Kohnoe S, Sugimachi K. Human colon cancer tissues are more sensitive than rectal cancer tissues to antitumor drugs in vitro. Oncology 1991;48:158-61.
11. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995;1:301-11.
12. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
13. Yamaue H, Tanimura H, Tsunoda T, et al. Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay. Eur J Cancer 1991;27:1258-63.
14. Yamaue H, Tanimura H, Noguchi K, et al. Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. Br J Cancer 1992;66:794-9.
15. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH, Von Hoff D. Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 1986; 70:1379-82.
16. Ferguson PJ, Cheng Y. Phenotypic instability of drug sensitivity in a human colon carcinoma cell line. Cancer Res 1989;49;1148-53.
17. Saikawa Y, Kubota T, Furukawa T, et al. Single-cell suspension assay with an MTT end point is useful for evaluating the optimal adjuvant chemotherapy for advanced gastric cancer. Jpn J Cancer Res 1994;85:762-5.
18. Park JG, Kramer BS, Steinberg SM, et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 1987;47;5875-9.
19. Campling BG, Baker HM, Cole SP, Lam YM. Chemosensitivity testing of small cell lung cancer using the MTT assay. Br J Cancer 1991;63:75-83.
20. Kaspers GJ, Pieters R, Van Zantwijk CH, et al. In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemia cells from bone marrow and peripheral blood. Br J Cancer 1991;64:469-74.
21. Trotter GA, Morgan GR, Goeting N, Cooper AJ, Taylor I. Prognostic factors and in vitro cytotoxic sensitivity in colorectal cancer. Br J Surg 1984;71:944-6.
22. Sobrero AF, Aschele C, Guglielmi AP, et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993;85: 1937-44.
23. Franchi F, Barone C, Seminara P, et al. 5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short term tumor cultures. Med Oncol Tumor Pharmacothcr 1991;8:75-8.
24. DeSimone PA, Davila E, Jochimsen PR, Bartolucci AA. High-dose cisplatin in the treatment of advanced adenocarcinoma of the colon and rectum: a southeastern cancer study group trial. Cancer Treat Rep 1986;70: 1229-30.
25. Loehrer PJ, Turner SS, Kubilis P, et al. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier oncology group trial. J Clin Oncol 1988; 6:642-8.
26. Loehrer PJ, Einhorn LH, Williams SD, Hui SL, Estes NC, Pennington K. Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon. Cancer Treat Rep 1985; 69:1359-63.
27. Villa R, Zaffaroni N, Orlandi L, Bearzatto A, Costa A, Silvestrini R. In vitro effect of lonidamine on the cytotoxicity of mitomycin C and BCNU in human colon adenocarcinoma cells. Eur J Cancer 1994;30;1534-40.
28. Cortesi E, Capussotti L, Di Tora P, et al. Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5- fluorouracil chemotherapy for unresectable colorectal metastases. Dis Colon Rectum 1994; 37(Suppl):S138-43.
29. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorode-oxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-93.
30. Martin JK, O'Connell MJ, Wieand HS, et al. Intraarterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990;125: 1022-7.